Abstracts tagged "Antiphospholipid syndrome and monocytes"

Abstract Number: 2764 • 2017 ACR/ARHP Annual Meeting
Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease
Patricia Ruiz-Limon¹, Carlos Perez-Sanchez², Maria Ángeles Aguirre Zamorano², Irene Cecchi³, Nuria Barbarroja², Yolanda Jiménez-Gómez², Ivan Arias de la Rosa¹, Maria Carmen Abalos-Aguilera¹, Pedro Segui⁴, Eduardo Collantes-Estévez², Maria Jose Cuadrado⁵ and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Monocytes are key players involved in the development of several autoimmune disease due to their capacity to modulate lipid metabolism, secrete inflammatory cytokines, chemokines,…
Abstract Number: 1729 • 2012 ACR/ARHP Annual Meeting
Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes
Yuichiro Fujieda¹, Olga Amengual¹, Yusaku Kanetsuka¹, Toshio Odani¹, Kotaro Otomo¹, Kenji Oku², Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹, Kimiko Kuroki³, Katsumi Maenaka³, Masaki Matsumoto⁴, Shigetsugu Hatakeyama⁵ and Tatsuya Atsumi⁶, ¹Hokkaido University,Medicine II, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Hokkaido University,Laboratory of Biomolecular Science, Sapporo, Japan, ⁴Kyusyu University,Divison of proteomics, Multi-scale Reserch Center for Prevention of Medical Science, Fukuoka, Japan, ⁵Hokkaido University,Biochemistry, Sapporo, Japan, ⁶Medicine II, Hokkaido University,Medicine II, Sapporo, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thrombosis and the presence of antiphospholipid antibodies (aPL). Tissue factor (TF), the major initiator of the extrinsic coagulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].